A Phase 3 interventional study of ABX464 and Placebo in Ulcerative Colitis, sponsored by Abivax S.A.. Active, not recruiting at 413 sites in 34 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Abivax S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 17th largest by enrollment of the 499 interventional ones that give a count, is one of 35 that started in 2023, is one of 116 in phase 3, reaches primary completion later than 31 of the 165 other live ones, and was the 467th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 35 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,116 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.
All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 study which consists of 2 treatment phases.
This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
The maintenance phase is a 44-week double blind, placebo-controlled, phase. Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2.
At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded.
Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment. Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.
Inclusion Criteria in maintenance phase:
Inclusion criteria in LTE phase:
Exclusion Criteria in maintenance phase:
Exclusion criteria for LTE phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be orally dosed during 44 weeks
Drug: ABX464
Subjects will be orally dosed during 44 weeks
Drug: ABX464
Subjects will be orally dosed during 44 weeks
Drug: Placebo
Subjects will be orally dosed during 44 weeks
Drug: ABX464
Subjects will be orally dosed during 44 weeks
Drug: ABX464
At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.
Drug: ABX464
Administered once daily, preferably in the morning, with food
Also known as: Obefazimod
Administered once daily, preferably in the morning, with food
Rate of subjects in clinical remission at Week 44
The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Week 44.
Time frame: Week 44
Number and percentage of all treatment-emergent adverse events (TEAEs)
The Part 2 primary objective is safety
Time frame: Week 44
Number and percentage of all serious adverse events (SAEs)
The Part 2 primary objective is safety
Time frame: Week 44
Number and percentage of all causally related TEAEs/SAEs
The Part 2 primary objective is safety
Time frame: Week 44
Proportion of subjects with endoscopic improvement at Week 44
To compare the efficacy of ABX464 versus placebo on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1) at Week 44
Time frame: Week 44
Proportion of subjects with corticosteroid-free clinical remission
To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)
Time frame: Week 44
Proportion of subjects with sustained clinical remission at Week 44
To compare the efficacy of ABX464 versus placebo to sustain clinical remission at Week 44
Time frame: Week 44
Proportion of subjects with HEMI per Geboes scoring at Week 44
To evaluate the efficacy of ABX464 on histologic-endoscopic mucosal improvement (HEMI) versus placebo at Week 44
Time frame: Week 44
Proportion of subjects with endoscopic remission at Week 44
To compare the efficacy of ABX464 versus placebo on endoscopic remission (MES = 0) at Week 44
Time frame: Week 44
LTE Phase - Proportion of subjects in clinical remission at Year 1
To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 1
Time frame: LTE Year 1
LTE Phase - Proportion of subjects in clinical remission at Year 4
To evaluate the efficacy of obefazimod on clinical remission \[SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1\] at Year 4
Time frame: LTE Year 4
LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry
To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and corticosteroid free for at least 12 weeks prior to Year 1 in the subpopulation with corticosteroids at maintenance study entry)
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with corticosteroid-free clinical remission in the subpopulation with corticosteroids at maintenance study entry)
To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and corticosteroid free for at least 12 weeks prior to Year 4 in the subpopulation with corticosteroids at maintenance study entry)
Time frame: LTE Year 4
LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 1
To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with endoscopic improvement at LTE Year 4
To evaluate the efficacy of obefazimod on endoscopic improvement (Mayo Endoscopic Subscore (MES) = 0 or 1)
Time frame: LTE Year 4
LTE Phase - Proportion of subjects with endoscopic remission at LTE year 1
To evaluate the efficacy of obefazimod on endoscopic remission ((Mayo Endoscopic Subscore (MES) = 0)
Time frame: LTE year 1
LTE Phase - Proportion of subjects with endoscopic remission at LTE year 4
To evaluate the efficacy of obefazimod on endoscopic remission (Mayo Endoscopic Subscore (MES) = 0)
Time frame: LTE year 4
LTE Phase - Proportion of subjects with CS-free symptomatic remission by visit
To evaluate the efficacy of obefazimod on CS-free symptomatic remission (symptomatic remission (SFS = 0 or 1 and RBS = 0) and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry) by visit (every 3-month)
Time frame: 4 years
LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 1
To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with HEMI per Geboes scoring at LTE Year 4
To evaluate the efficacy of obefazimod on histologic endoscopic mucosal improvement (HEMI) per Geboes scoring
Time frame: LTE Year 4
LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 1
To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with HEMR per Geboes scoring at LTE Year 4
To evaluate the efficacy of obefazimod on histologic endoscopic mucosal remission (HEMR) versus placebo
Time frame: LTE Year 4
LTE Phase - Proportion of subjects with sustained clinical remission at LTE Year 1, in the sub-population of subjects with clinical remission at Week 44
To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with sustained clinical remission at LTE year 4, in the sub-population of subjects with clinical remission at Week 44
To evaluate the efficacy of obefazimod on sustained clinical remission Sustained clinical remission for the LTE is defined as clinical remission assessed at an endoscopy visit during the LTE in the sub-population of subjects in clinical remission at Week 44.
Time frame: LTE year 4
LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 1, in the sub-population of subjects with endoscopic improvement at Week 44
To evaluate the efficacy of obefazimod on sustained endoscopic improvement
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with sustained endoscopic improvement at LTE Year 4, in the sub-population of subjects with endoscopic improvement at Week 44
To evaluate the efficacy of obefazimod on sustained endoscopic improvement
Time frame: LTE year 4
LTE Phase - Proportion of subjects with symptomatic remission by visit
To evaluate the efficacy of obefazimod on symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month)
Time frame: 4 years
LTE Phase - Proportion of subjects with sustained symptomatic remission by visit
To evaluate the efficacy of obefazimod on sustained symptomatic remission (SFS = 0 or 1 and RBS = 0) by visit (every 3-month), in the sub-population of subjects with symptomatic remission at Week 44
Time frame: 4 years
LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 1
To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 1 and CS-free for at least 12 weeks immediately prior to Year 1)
Time frame: LTE Year 1
LTE Phase - Proportion of subjects with CS-free clinical remission at LTE Year 4
To evaluate the efficacy of obefazimod on CS-free clinical remission (clinical remission at Year 4 and CS-free for at least 12 weeks immediately prior to Year 4)
Time frame: LTE Year 4
Showing the first 100 of 413 sites across 34 countries. Choose a country and city above to see the rest.
Ran from Jan 2023 to primary completion in Apr 2026, 39 months.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 39 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464